Advanced Accelerator Applications is a leading brand that is revolutionizing nuclear medicine and cancer care. Their mission is to transform the lives of patients by developing and delivering innovative targeted radioligand therapies and precision imaging radioligands for oncology. With a focus on prostate cancer and neuroendocrine cancer, they are dedicated to discovering and developing nuclear medicine for cancer treatment.

Their expertise is built on a 15-year legacy of manufacturing a diverse portfolio of PET and SPECT nuclear medicine imaging products for various indications in oncology, neurology, cardiology, and infectious diseases. As part of their commitment to advancing medical solutions, they conduct clinical trials to find new and improved ways to diagnose and treat diseases. With over 1,000 associates across 12 countries, Advanced Accelerator Applications is a key platform of the Novartis Bold4Cure strategy.

They are driven by their belief that targeted radioligand therapy has the potential to be used in different tumor types, making it an exciting time in their development